Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer

Overview of attention for article published in European Urology Focus , March 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (72nd percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

So far, Altmetric has seen 7 tweets from 7 users, with an upper bound of 4,860 followers.

New article: Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer https://t.co/zPSBr0xu0Z #prostatecancer #oncology https://t.co/AWXdf1nt8Y

RT @ProBioTrial: The #ProstateCancer #PrecisionOncology @ProBioTrial has acquired EC/RA approval for a substantial amendment, which we are…

RT @ProBioTrial: The #ProstateCancer #PrecisionOncology @ProBioTrial has acquired EC/RA approval for a substantial amendment, which we are…

RT @ProBioTrial: The #ProstateCancer #PrecisionOncology @ProBioTrial has acquired EC/RA approval for a substantial amendment, which we are…

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 3 additional tweets.